Cargando…

264 Effective Reduction of Diabetic Nephropathy-Induced Albuminuria With SGLT2 inhibitor Monotherapy

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973165/ http://dx.doi.org/10.1053/j.ajkd.2021.02.269

Ejemplares similares

Renoprotective potential of concomittant medications with SGLT2 inhibitors and renin-angiotensin system inhibitors in diabetic nephropathy without albuminuria: a retrospective cohort study
por: Ishibashi, Tatsuya, et al.
Publicado: (2023)

Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy
por: Dong, Yaping, et al.
Publicado: (2023)

Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction
por: Sato, Saeko, et al.
Publicado: (2022)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
por: Bessho, Ryoichi, et al.
Publicado: (2019)

THU360 Hyperglycemic DKA In Patient On Monotherapy With SGLT-2 Inhibitor
por: Ahmed, Samihah, et al.
Publicado: (2023)

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
por: Maki, Toshinobu, et al.
Publicado: (2019)

Determination of albuminuria in the urine of diabetics for prevention and control of diabetic nephropathy
por: Schroeder, Andreas, et al.
Publicado: (2005)

The Effect of SGLT2 Inhibitors on the Development of Contrast-Induced Nephropathy in Diabetic Patients with Non-ST Segment Elevation Myocardial Infarction
por: Özkan, Uğur, et al.
Publicado: (2023)

SGLT2 inhibition to address the unmet needs in diabetic nephropathy
por: Barutta, Federica, et al.
Publicado: (2019)

The association between monocyte HDL ratio and albuminuria in diabetic nephropathy
por: Efe, Fatma Kaplan
Publicado: (2021)

Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
por: Gallo, Linda A., et al.
Publicado: (2016)

Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy
por: Stangenberg, Stefanie, et al.
Publicado: (2018)

ROCK1 Induces Endothelial-to-Mesenchymal Transition in Glomeruli to Aggravate Albuminuria in Diabetic Nephropathy
por: Peng, Hui, et al.
Publicado: (2016)

SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β(1) secretion in type 2 diabetes patients with albuminuria: a randomized clinical trial
por: Tian, Yuan, et al.
Publicado: (2022)

A Study of Association of Urinary Nephrin with Albuminuria in Patients with Diabetic Nephropathy
por: Kondapi, Kishore, et al.
Publicado: (2021)

Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy
por: Barutta, Federica, et al.
Publicado: (2010)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
por: Cho, Hyun A, et al.
Publicado: (2017)

Association between Pro12Ala polymorphism and albuminuria in type 2 diabetic nephropathy
por: Chen, Yung‐Nien, et al.
Publicado: (2020)

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
por: Rosenstock, Julio, et al.
Publicado: (2015)

Erratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
por: Gallo, Linda A., et al.
Publicado: (2016)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy
por: Kim, Hyoungnae, et al.
Publicado: (2019)

2 year followup of patients with diabetes mellitus nephropathy showing albuminuria reversal following angiotensin converting enzyme inhibitors
por: Gopinath, S., et al.
Publicado: (2012)

Mechanism of Albuminuria Reduction by Chymase Inhibition in Diabetic Mice
por: Terai, Kentaro, et al.
Publicado: (2020)

PSUN199 SGLT2-Inhibitor Prescription Rates in Individuals with Diabetic Nephropathy at a Teaching Outpatient Clinic
por: Abdulwahid, Tiba, et al.
Publicado: (2022)

Addition of nonalbumin proteinuria to albuminuria improves prediction of type 2 diabetic nephropathy progression
por: Kim, Jong Ho, et al.
Publicado: (2017)

Serum chromogranin A correlated with albuminuria in diabetic patients and is associated with early diabetic nephropathy
por: Yu, Hui, et al.
Publicado: (2022)

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
por: Panchapakesan, Usha, et al.
Publicado: (2013)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy
por: MA, RUIXIA, et al.
Publicado: (2013)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model
por: Kajiwara, Koichiro, et al.
Publicado: (2021)

Utility of Urinary Nephrin in Patients With and Without Diabetic Nephropathy and Its Correlation With Albuminuria
por: Surya, Manupati, et al.
Publicado: (2021)

Letter Regarding Normal Albuminuria in Patients With Autopsy-Proven Advanced Diabetic Nephropathy
por: Heyman, Samuel N., et al.
Publicado: (2022)

SGLT2 Inhibitors and Kidney and Cardiac Outcomes According to Estimated GFR and Albuminuria Levels: A Meta-analysis of Randomized Controlled Trials
por: Chun, Kwang Jin, et al.
Publicado: (2021)

A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022)

Aldosterone Antagonists in Monotherapy Are Protective against Streptozotocin-Induced Diabetic Nephropathy in Rats
por: Banki, Nora F., et al.
Publicado: (2012)

Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors
por: Kogot-Levin, Aviram, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ek2gaoem84i49or9l4243r5t6j